Bacil Pharma submits audited financial results for FY26

0 min read Updated on 05 Jun 2026, 05:49 PM

Reviewed by

Suketu GScanX News Team

AI Summary

Bacil Pharma Limited submitted newspaper clippings for its audited financial results for the quarter and year ended March 31, 2026, to BSE Ltd. The results were published in Marathi and English on June 3, 2026, complying with SEBI (LODR) Regulations.

*this image is generated using AI for illustrative purposes only.

bacil pharma has submitted newspaper clippings for its audited financial results for the quarter and year ended March 31, 2026, to BSE Ltd. The submission was made pursuant to Regulation 47(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were published in both Marathi and English newspapers on June 3, 2026.

The company provided the clippings to the General Manager (DCS) at BSE Ltd. for their records. The filing confirms that Bacil Pharma Limited has complied with the regulatory requirement to disclose its audited financial performance for the specified period.

Regulatory Compliance

The submission is a mandatory disclosure under SEBI regulations. The company ensured the results were published in two languages to meet the requirements. The document was signed by Ms. Chaitali Kalpataru Shah, Director & CFO of Bacil Pharma Limited.

Key Details

Detail	Information
Company	Bacil Pharma Limited
Period Ended	March 31, 2026
Publication Date	June 3, 2026
Regulation	SEBI (LODR) Regulation, 2015
Signatory	Ms. Chaitali Kalpataru Shah (Director & CFO)

Historical Stock Returns for Bacil Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.33%	-4.09%	-12.00%	+19.08%	+24.11%	+566.67%

How will the audited financial results for FY26 impact Bacil Pharma's stock performance in the upcoming quarter?

What strategic initiatives is Bacil Pharma planning to drive growth in the post-FY26 period?

How might regulatory changes in the pharmaceutical sector affect Bacil Pharma's compliance and operational costs?

Read Next Article

Bacil Pharma Limited Discloses Nil Related Party Transactions for Quarter/Half Year Ended March 31, 2026

1 min read Updated on 23 May 2026, 12:15 AM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

AI Summary

Bacil Pharma Limited has filed a disclosure with BSE Limited confirming nil related party transactions for the quarter/half year ended March 31, 2026, under Regulation 23(9) of the SEBI (LODR) Regulations, 2015. The filing was dated May 22, 2026, and submitted from Mumbai. The disclosure was signed by Ms. Chaitali Kalpataru Shah, Director & CFO, bearing DIN: 11167778.

*this image is generated using AI for illustrative purposes only.

Bacil Pharma Limited has informed BSE Limited that it did not enter into any related party transactions during the quarter/half year ended March 31, 2026. The disclosure was filed pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the related party transaction details have accordingly been submitted as "Nil" for the said period.

Regulatory Filing Details

The company submitted the disclosure to the Listing Compliance Department of BSE Limited on May 22, 2026. The filing was made in the prescribed format as required under the applicable SEBI Circular. Key details of the filing are summarised below:

Parameter:	Details
Filing Date:	May 22, 2026
Period Covered:	Quarter/Half Year ended March 31, 2026
Regulation:	Regulation 23(9), SEBI (LODR) Regulations, 2015
Related Party Transactions:	Nil
Exchange:	BSE Limited
Signed By:	Ms. Chaitali Kalpataru Shah, Director & CFO
Place:	Mumbai

Signatory Information

The disclosure was digitally signed and submitted by Ms. Chaitali Kalpataru Shah, who serves as Director & Chief Financial Officer of Bacil Pharma Limited, bearing DIN: 11167778. The filing was made from the company's registered office located at G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai – 400099.

The submission confirms the company's compliance with its periodic disclosure obligations under SEBI's listing regulations for the relevant reporting period.

Historical Stock Returns for Bacil Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.33%	-4.09%	-12.00%	+19.08%	+24.11%	+566.67%

How does Bacil Pharma's consistent absence of related party transactions compare to industry peers, and could this signal a more conservative corporate governance approach that might attract institutional investors?

As Bacil Pharma scales its operations, what types of related party transactions might emerge in future quarters, and how could they impact minority shareholder interests?

Could the nil related party transactions indicate limited business expansion or strategic partnerships, and what does this suggest about Bacil Pharma's growth trajectory for FY2027?